Searched for
SUN PHARMA DEAL
India's current account deficit to remain 1.5-1.7% of GDP in FY27 but RBI measures may turn BoP surplus: SBI ReportIndia's current account deficit is projected for FY27. However, Reserve Bank of India measures are anticipated to improve the country's ext...- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Why stock market crashed today? Sensex sinks 1,100 points, Nifty below 23,550. 4 key factorsIndian stock markets experienced a sharp downturn Friday, with Sensex and Nifty falling significantly due to persistent foreign investor se...
- Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmerIndian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their ef...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Sensex slips 250 pts, Nifty at 24,000 as US strike on Iran dent sentiment; mid, smallcaps outperformBenchmark indices Nifty and Sensex traded marginally lower on Tuesday, impacted by US attacks in southern Iran, reigniting fears of a prolo...
- Why market rallied today? Sensex jumps 1,074 points, Nifty closes above 24,000. 5 factors behind surgeIndian stock markets surged on Monday, with Sensex and Nifty rallying over 1% each, driven by rising hopes of a US-Iran peace deal and fall...
- Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...
- Market wrap: Sensex rises 232 points, Nifty closes above 23,700 as rupee recovers from lifetime lowsIndian markets ended the week higher after recovering intraday volatility, with Sensex and Nifty posting modest gains amid hopes of easing ...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Why did the stock market fall today? Sensex tumbles 1,300 pts, Nifty below 23,850. 6 key factorsIndian stock markets experienced a significant downturn on Monday. The Sensex and Nifty saw sharp declines as oil prices surged. Fading hop...
- Buy capital goods on dips, stay cautious on IT and consumption: Sudip BandyopadhyayMarket expert Sudip Bandyopadhyay outlines investment strategies across key sectors. He sees opportunities in State Bank of India and a gen...
- Sun Pharma explores funding mix for $12 billion Organon dealGlobal lenders are exploring various financing options for Sun Pharmaceutical Industries' proposed $12 billion acquisition of Organon & Co....
- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Organon gives Sun Pharma scale and reach, but challenge lies in integration, executionSun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It ...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
Load More
